NOV INC (NOV)       23.27  +0.31 (+1.35%)

23.27  +0.31 (+1.35%)

US62955J1034 - Common Stock - After market: 23.27 0 (0%)


Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to NOV. NOV was compared to 91 industry peers in the Energy Equipment & Services industry. The financial health of NOV is medium. Also its profitability is quite bad. NOV is valued quite expensive, but it does show an excellent growth.




Profitability

Profitability Rating

1

The Piotroski-F score of NOV is 5.00. This is a neutral score and indicates average health and profitability for NOV.
NOV has a Return On Assets of 0.11%. This is below the industry average of 6.20%. 100% of the industry peers outperform NOV.

NOV has a Return On Equity of 0.23%. This is below the industry average of 12.38%. 100% of the industry peers outperform NOV.
NOV's Profit Margin of 0.16% is worse than the rest of the industry. The industry average Profit Margin is 7.74%. 100% of the industry peers have a better Profit Margin.
VS Industry

ROA (0.11%) VS Industry: 0% outperformed.

0.11
85,176.32

ROE (0.23%) VS Industry: 0% outperformed.

0.23
39.13

Profit Margin (0.16%) VS Industry: 0% outperformed.

0.16
114.10

Valuation

Valuation Rating

3

The low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
With a Forward Price/Earnings Ratio of 20.23, NOV is valued rather expensively.
With a price book ratio of 1.88, NOV is valued correctly.
The Price/Earnings Ratio is 110.81, which means the current valuation is very expensive for NOV.

Compared to an average industry Price/Earning Ratio of 22.06, NOV is valued more expensive than its industry peers. On top of this 100% of the companies listed in the same industry are cheaper than NOV!
Compared to an average industry price book ratio of 1.46, NOV is valued more expensive than its industry peers.
Compared to an average industry Enterprise Value to EBITDA ratio of 9.78, NOV is valued more expensive than its industry peers. 91% of the companies listed in the same industry are valued cheaper.
VS Industry

Price/Earnings (110.81) VS Industry: 0% outperformed.

110.81
0.07

Price/Book (1.88) VS Industry: 34% outperformed.

29.01
0.27

Enterprise Value/ EBITDA (26.12) VS Industry: 9% outperformed.

386.61
3.42

Growth

Growth Rating

8

NOV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 129.58%, which is quite impressive.
The Earnings Per Share is expected to grow by 42.61% on average over the next 5 years. This is a very strong growth
Looking at the last year, NOV shows a very strong growth in Revenue. The Revenue has grown by 25.25%.

Based on estimates for the next 5 years, NOV will show a quite strong growth in Revenue. The Revenue will grow by 13.03% on average per year.
The Revenue growth is accelerating: in the next 5 years the growth will be better than in the last years.
NOV shows a decrease in Revenue. Measured over the last 5 years, the Revenue has been decreasing by -5.30% yearly.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 129.58% 222.83% 107.38% 72.69% 42.61%
Revenue-5.3% -13.22% 25.25% 31.65% 23.05% 18.84% 13.03%

Health

Health Rating

6

NOV has a Current Ratio of 2.30. This indicates that NOV is financially healthy and has no problem in meeting its short term obligations.
NOV is better placed than average in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 1.80.
NOV is better placed than average in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 1.37.
A Quick Ratio of 1.52 indicates that NOV should not have too much problems paying its short term obligations.

The Debt to Equity ratio of NOV is in line with the industry averages.
NOV has an Altman-Z score of 1.89. This is not the best score and indicates that NOV is in the grey zone with still only limited risk for bankruptcy at the moment.
NOV has a Altman-Z score comparable to the industry average, which is at 1.69.
The Piotroski-F score of NOV is 5.00. This is a neutral score and indicates average health and profitability for NOV.
VS Industry

Debt/Equity (0.4) VS Industry: 46% outperformed.

5.89
0.00

Quick Ratio (1.52) VS Industry: 63% outperformed.

0.25
8.35

Current Ratio (2.3) VS Industry: 71% outperformed.

0.32
8.43

Altman-Z (1.89) VS Industry: 53% outperformed.

-4,843.59
13.84

Dividend

Dividend Rating

2

NOV has been paying a dividend for at least 10 years, so it has a reliable track record.
With a yearly dividend of 0.87%, NOV is not a good candidate for dividend investing.
With a Dividend Yield of 0.87, NOV pays less dividend than the industry average, which is at 2.13. 93% of the companies listed in the same industry pay a better dividend than NOV!

Compared to an average S&P500 Dividend Yield of 2.41, NOV's dividend is way lower than the S&P500 average.
The dividend of NOV decreases each year by -37.00%.
718.18% of the earnings are spent on dividend by NOV. This is not a sustainable payout ratio.
VS Industry

Dividend Yield (0.87%) VS Industry: 7% outperformed.

0.16
11.44

NOV INC23.27

NYSE:NOV (2/3/2023, 7:04:01 PM)+0.31 (+1.35%)

After market: 23.27 0 (0%)

Chartmill FA Rating
GICS Sector Energy
GICS IndustryGroup Energy
GICS Industry Energy Equipment & Services
Earnings (Last) 10-27 2022-10-27/amc Earnings (Next) 02-06 2023-02-06/amc
Inst Owners 93.31% Inst Owner Change -1.71%
Ins Owners 0.65% Ins Owner Change -0.66%
Market Cap 9.14B Analysts 77.14
Price Target 26.2 (12.59%)

Dividend
Industry RankSector Rank
Dividend Yield 0.87%
Dividend Growth(5Y) -37% DP 718.18%
Div Incr Years 1 Div Non Decr Years 2
Ex-Date N/A

Surprises & Revisions
EPS beat(2) 1 Avg EPS beat(2) 207.23%
Min EPS beat(2) -51.76% Max EPS beat(2) 466.21%
EPS beat(4) 2 Avg EPS beat(4) 89.62%
Min EPS beat(4) -137.65% Max EPS beat(4) 466.21%
Revenue beat(2) 2 Avg Revenue beat(2) 3.77%
Min Revenue beat(2) 2.94% Max Revenue beat(2) 4.6%
Revenue beat(4) 4 Avg Revenue beat(4) 2.61%
Min Revenue beat(4) 0.39% Max Revenue beat(4) 4.6%
PT rev (1m) 1.25% PT rev (3m) 13.74%
EPS NQ rev (1m) 1.23% EPS NQ rev (3m) 6.72%
EPS NY rev (1m) 0% EPS NY rev (3m) 9.21%
Revenue NQ rev (1m) 0% Revenue NQ rev (3m) 1.1%
Revenue NY rev (1m) 0% Revenue NY rev (3m) 0.92%

Valuation
Industry RankSector Rank
PE 110.81
Fwd PE 20.23
P/S 1.37
P/FCF N/A
P/OCF N/A
P/B 1.88
P/tB 3.19
EV/EBITDA 26.12
EPS(TTM) 0.21 EY 0.9%
EPS(NY) 1.15 Fwd EY 4.94%
FCF(TTM) -1.3 FCFY N/A
OCF(TTM) -0.76 OCFY N/A
SpS 17.01 BVpS 12.39
TBVpS 7.29 PEG (NY) 0.5
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA 0.11%
ROE 0.23%
ROIC 0.91%
ROICexc 1.05%
ROICexgc 1.52%
OM 1.3%
PM 0.16%
GM 16.36%
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y N/A ROICexc growth 5Y N/A
OM growth 3Y N/A OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y -6.39% GM growth 5Y N/A
F-Score 5 Asset Turnover 0.68

Health
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Debt/EBITDA 5.07
Cap/Depr 70.67%
Profit Quality N/A
Current Ratio 2.3
Quick Ratio 1.52
Altman-Z 1.89
F-Score 5 WACC 11.78%
ROIC/WACC 0.13 Cap/Depr(3y) 57.87%
Cap/Depr(5y) 47.3% Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y 129.58% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 166.67%
EPS Next Y 222.83% EPS Next 2Y 107.38%
EPS Next 3Y 72.69% EPS Next 5Y 42.61%
Revenue growth 1Y 25.25% Revenue growth 3Y -13.22%
Revenue growth 5Y -5.3% Revenue growth Q2Q 40.87%
Revenue Next Year 31.65% Revenue Next 2Y 23.05%
Revenue Next 3Y 18.84% Revenue Next 5Y 13.03%
EBIT growth 1Y 120.71% EBIT growth 3Y N/A
EBIT growth 5Y N/A EBIT Next Year 998.12%
EBIT Next 3Y 162.55% EBIT Next 5Y 82.23%
FCF growth 1Y -152.31% FCF growth 3Y -31.25%
FCF growth 5Y -33.19% OCF growth 1Y -124.48%
OCF growth 3Y -17.65% OCF growth 5Y -21.24%

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA